Pharmaceutical Organizational Size and Phase 3 Clinical Trial Completion Times

Conclusions:
Recent years have witnessed increasingly larger pharmaceutical R&D organizations, as many companies have worked to achieve the scale benefits of organizational size for R&D as well as commercial activity. Larger pharmaceutical companies may still achieve scale benefits. Faster phase 3 study completion times is not one of them.

Source: Therapeutic Innovation and Regulatory Science - October 23, 2016 Category: Drugs & Pharmacology Authors: Glass, H. E., Glass, L. M., Tran, P., Alghamdi, H. Tags: Clinical Trials Source Type: research